Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 3/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.36 |
| ▸ | LPL | P06858 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2150588 | 1.00 | AAK1 (0.52) | AAK1HIF1ACA1CA2CA9 | |
| SCHEMBL14664424 | 1.00 | AAK1 (0.52) | AAK1HIF1ACA1CA2CA9 | |
| SCHEMBL21572110 | 0.93 | AAK1 (0.50) | AAK1HIF1ACA1CA2CA9 | |
| SCHEMBL21877165 | 0.91 | AAK1 (0.52) | AAK1HIF1ACA1CA2CA9 | |
| SCHEMBL20294880 | 0.91 | AAK1 (0.52) | AAK1HIF1ACA1CA2CA9 | |
| SCHEMBL20317435 | 0.89 | AAK1 (0.53) | AAK1HIF1ACA1CA2CA9 | |
| SCHEMBL20294529 | 0.89 | AAK1 (0.54) | AAK1HIF1ACA1CA2CA9 | |
| SCHEMBL25294268 | 0.87 | AAK1 (0.53) | AAK1HIF1ACA1CA2CA9 | |
| SCHEMBL12224514 | 0.84 | LIPG (0.47) | AAK1HIF1ACA1CA2CA9 | |
| SCHEMBL12224516 | 0.84 | LIPG (0.47) | AAK1HIF1ACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230273215-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230251264-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN, INC. | 2023-08-10 | — | — | US | disclosed |
| US-9547008-B2 | Reagents for directed biomarker signal amplification | SIRIGEN INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160349267-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN GROUP LIMITED (GB) | 2016-12-01 | — | — | US | disclosed |
| US-20160025735-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN GROUP LIMITED (GB) | 2016-01-28 | — | — | US | disclosed |
| US-9139869-B2 | Reagents for directed biomarker signal amplification | SIRIGEN INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20110256549-A1 | Novel reagents for directed biomarker signal amplification | SIRIGEN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160349267-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | AAK1 3825/4885HIF1A 2283/4885CA1 541/4885 |
| US-20110256549-A1 | Novel reagents for directed biomarker signal amplification | RNGTT, CAPG, CD2BP2 | AAK1 3825/4885HIF1A 2283/4885CA1 541/4885 |
| US-20230251264-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | AAK1 3825/4885HIF1A 2283/4885CA1 541/4885 |
| US-20230273215-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | AAK1 3825/4885HIF1A 2283/4885CA1 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.